Company Showcase

Your trusted end-to-end CDMO partner


Mitigating Risks Associated With Single-Use Systems: Critical Considerations


Embracing Necessary Digital Transformation in Biomanufacturing


Samsung Biologics' Plant 4

Posted By

Seulgi Ju

Account Manager

[email protected]

Jina Kim

Account Manager

[email protected]

Samsung Biologics is a fully integrated CDMO partner providing highly tailored solutions to each client. Our end-to-end services include upstream and downstream process development, clinical and commercial manufacturing, aseptic fill/finish, and analytical and biosafety testing—all from a single location. Our plants are cGMP compliant holding 364KL total capacity with wide range of 1KL, 5KL, 15KL scale bioreactors. To meet the growing market demand, we are currently expanding manufacturing capacity with the new plant 4 with additional 264KL. 

Sales Markets

North America (USA, Canada); East Asia (e.g. China, Japan, Korea); Europe - EU countries

Primary business activity

Contract Service

Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information




View All Contact Info

Our Resources

Categories affiliated with Samsung Biologics Co., Ltd.